Latest News and Press Releases

BRISBANE, AUSTRALIA--(Marketwired - Feb 19, 2014) - Alchemia Limited (ASX: ACL), a drug discovery and development company, today reports profit share of A$2.8 million (US$2.5 million) for the...

MELBOURNE, AUSTRALIA--(Marketwired - Feb 18, 2014) - Nexvet Biopharma, a leading veterinary biologic drug developer, today announced that Dr Mark Heffernan, Nexvet's Chief Executive Officer, is...

BRISBANE, AUSTRALIA--(Marketwired - Feb 18, 2014) - Alchemia Limited, (ASX: ACL) a drug discovery and development company, is pleased to announce its half year results for the six months ended 31...

MELBOURNE, AUSTRALIA--(Marketwired - Feb 12, 2014) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that it received a further ExParte Re-Examination Certificate from the...

BRISBANE, AUSTRALIA--(Marketwired - Feb 11, 2014) - Alchemia Limited, (ASX: ACL) a drug discovery and development company, today announced the appointment of Santo J. Costa as non-executive...

MELBOURNE, AUSTRALIA--(Marketwired - Jan 30, 2014) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) Total sales revenue for BREVAGen™ test increased 50%...

MELBOURNE, AUSTRALIA--(Marketwired - Jan 8, 2014) - Genetic Technologies Limited (NASDAQ: GENE) (ASX: GTG) today announced that a new record number of BREVAGen™ test samples were received...

MELBOURNE, AUSTRALIA--(Marketwired - Dec 23, 2013) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that the Redeemable Convertible Note (the "Note") described in the...

MELBOURNE, AUSTRALIA--(Marketwired - Dec 18, 2013) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that entities associated with the Company's founder and largest...

MELBOURNE, AUSTRALIA--(Marketwired - Dec 6, 2013) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced its flagship genetic breast cancer risk prediction test, BREVAGen™,...